Illumina ILMN · NASDAQ
$262.66 +0.05% (+$0.12)
Summary
59 / 100 · Bulios Score
What speaks for it
- Out of every 100 USD of revenue, 18 USD is left as net profit.
- It earns 14 USD a year on every 100 USD of invested capital.
What to watch
- The share price is above the Bulios Fair Price.
- Revenue fell by 1.8% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Today you pay 48.1 USD for 1 USD of yearly profit.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue grew by 6.0% a year over 5 years. Over the last 3 years it fell by 1.8% a year. For the next fiscal year analysts expect revenue to fall by 1.3%.
Growth in detailDoes it make money?
Very wellWhere 100 USD of revenue goes
- Cost of sales 33 USD
- Research and development 21 USD
- Sales and administration 25 USD
- Taxes and other 2.6 USD
- Net profit 18 USD
Net profit, industry median (Medical - Diagnostics & Research) 8.8 USD
Out of every 100 USD of revenue, 18 USD is left as net profit.
Profitability in detailIs it financially healthy?
YesRepaying all its debt would take 2.7 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 27
- Hold 17
- Sell 6
Today's price within the analysts' price targets
The average target of $241 is 8.2% below today's price. 54% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Sequencing 92%
- Microarray 8.2%
By region
- Americas 55%
- EMEA 29%
- Asia Pacific 9.9%
- CHINA 5.6%
Sequencing brings in 92% of revenue.
Segments in detail